Expedition Raises $115M Series B
Expedition Therapeutics raised $115M to develop oral therapies for inflammatory and respiratory diseases.
Specialist biotech platforms are still raising large rounds when the clinical focus is clear.
What happened
Expedition Therapeutics raised a $115 million Series B to advance oral therapies targeting inflammatory and respiratory diseases.
The round brought together a large syndicate of life-sciences investors and strategic backers. The company is focused on drug programmes where oral therapies could offer a more convenient route than existing treatment approaches.
Why it matters
The biotech funding market has been selective, but large rounds are still available for companies with clear disease areas, credible science and strong investor support.
Inflammatory and respiratory diseases are broad markets with significant unmet need. A successful oral therapy could improve patient convenience and expand treatment options.
The bigger picture
Biotech investors are still willing to fund ambitious therapeutic companies, but the bar is higher. Platform language alone is not enough; companies need a convincing path from biology to clinical development.
Expedition’s round is a reminder that capital is still flowing into focused drug-development stories when the opportunity looks large enough.